Senaste uppdateringen :
29/10/2024
Antibiotikum   Ofloxacin  
injektion
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Anzatax Malaysia
Floxil Mexiko
Floxitril Indien
Floxstat Colombia, Ecuador, Mexiko
Istaflox Mexiko
Menefloks Turkiet
Oflocare Peru
Oflocet Marocko, Portugal, Tunisien
Oflogyl Venezuela
Ofloxacin Förenta Staterna
Ofloxacine Frankrike
Ofloxin Egypten
Ofloxol Malaysia
Surnox Spanien
Tabrin Grekland
Tarivid Irland, Luxemburg, Nederländerna, Norge, Österrike, Polen, Portugal, Saudi-Arabien, Schweiz, Storbritannien, Turkiet, Tyskland, Ungern
Zanocin Indien, Polen
Zanovid Indien
Zenflox Indien
Hänvisningar   injektion   Hänvisningar : Ofloxacin  
Typ Publikation
59 tidningen Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
182 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
249 tidningen Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 tidningen Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
444 tidningen Bornstein M, Kao SH, Mercorelli M, Verma S.
Stability of an ofloxacin injection in various infusion fluids.
Am J Hosp Pharm 1992 ; 49: 2756-2760.
889 tidningen Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM.
Ofloxacin intravenous. Compatibility with other antibacterial agents.
Pharm Weekbl [Sci] 1991 ; 13: 207-209.
921 tidningen Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1410 tidningen Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 tidningen Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1481 tidningen Messerschmidt W.
Kompatibilität von ofloxacin mit ampicillin.
Krankenhauspharmazie 1994 ; 9: 337-340.
1625 tidningen Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1668 tidningen Zhang Y, Xu QA, Trissel LA, Williams KY.
Compatibility and stability of linezolid injection admixed with three quinolone antibiotics.
Ann Pharmacotherapy 2000 ; 34: 996-1001.
1712 tidningen Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 tidningen Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 tidningen Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 tidningen Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 tidningen Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
2139 tidningen Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
2155 tidningen Battista C, Kane MP, Moon DG, Bailie GR.
Stability of ofloxacin in peritoneal dialysis solutions.
Perit Dial Int 1995 ; 15: 72-74.
3562 Laboratorium Ofloxacin (Tarivid®) - Summary of Product Characteristics
Sanofi 2014
3791 affisch Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3883 Laboratorium Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016

  Mentions Légales